T-DM1：I期HER2阳性乳腺癌有前景的辅助治疗选择——从临床角度解读ATEMPT试验结果 - Suppr

T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective.

作者信息

Kesireddy Meghana, Krishnamurthy Jairam

机构信息

Division of Hematology and Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.

出版信息

Gland Surg. 2025 Apr 30;14(4):785-790. doi: 10.21037/gs-2025-23. Epub 2025 Apr 25.

DOI:10.21037/gs-2025-23

PMID:40405946

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12093180/

Abstract

摘要

相似文献

T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective.T-DM1：I期HER2阳性乳腺癌有前景的辅助治疗选择——从临床角度解读ATEMPT试验结果

Gland Surg. 2025 Apr 30;14(4):785-790. doi: 10.21037/gs-2025-23. Epub 2025 Apr 25.

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer.ATEMPT试验（TBCRC 033）的局部治疗结果与毒性：一项II期随机试验，对比辅助性曲妥珠单抗恩美曲妥珠单抗与紫杉醇联合曲妥珠单抗用于I期HER2阳性乳腺癌女性患者的疗效。

Int J Radiat Oncol Biol Phys. 2022 May 1;113(1):117-124. doi: 10.1016/j.ijrobp.2021.12.173. Epub 2022 Jan 3.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.曲妥珠单抗美坦新偶联物对比紫杉醇联合曲妥珠单抗用于人表皮生长因子受体 2 阳性Ⅰ期乳腺癌：来自 ATEMPT 的 5 年结果和相关分析

J Clin Oncol. 2024 Nov;42(31):3652-3665. doi: 10.1200/JCO.23.02170. Epub 2024 Jun 27.

Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.辅助性曲妥珠单抗恩美曲妥珠单抗与紫杉醇联合曲妥珠单抗治疗Ⅰ期HER2阳性乳腺癌（ATEMPT）研究（TBCRC033）受试者的心脏结局：一项随机对照试验。

NPJ Breast Cancer. 2022 Feb 16;8(1):18. doi: 10.1038/s41523-022-00385-2.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.曲妥珠单抗-美坦新偶联物与曲妥珠单抗联合紫杉醇用于 I 期 HER2 阳性乳腺癌（ATEMPT）的辅助治疗：一项随机临床试验。

J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel and Trastuzumab in Stage I HER2-Positive Breast Cancer: The ATEMPT Trial.曲妥珠单抗-美坦新偶联物对比紫杉醇和曲妥珠单抗用于早期 HER2 阳性乳腺癌：ATEMPT 试验。

Ann Surg Oncol. 2024 Mar;31(3):1423-1427. doi: 10.1245/s10434-023-14766-9. Epub 2023 Dec 21.

De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.人表皮生长因子受体 2（HER2）阳性早期乳腺癌（BC）的降级策略：德国西部研究组辅助动态标志物调整个体化治疗试验的最终分析，该试验优化了早期 BC 的 HER2 和激素受体阳性患者的风险评估和治疗反应预测，随机 II 期试验比较了曲妥珠单抗恩坦辛联合或不联合内分泌治疗（ET）与曲妥珠单抗加 ET 的新辅助治疗 12 周的疗效、安全性和预测标志物。

J Clin Oncol. 2017 Sep 10;35(26):3046-3054. doi: 10.1200/JCO.2016.71.9815. Epub 2017 Jul 6.

Breast Cancer Res Treat. 2021 Aug;189(1):103-110. doi: 10.1007/s10549-021-06267-8. Epub 2021 Jun 12.

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine.使用曲妥珠单抗恩美曲妥珠单抗对HER2阳性乳腺癌进行分析和靶向治疗。

Pharmgenomics Pers Med. 2014 Oct 15;7:329-38. doi: 10.2147/PGPM.S47524. eCollection 2014.

Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States.帕妥珠单抗和 ado-trastuzumab emtansine 对美国局部晚期、炎性或早期 HER2 阳性乳腺癌女性患者复发累积避免的影响。

Adv Ther. 2023 Sep;40(9):3857-3874. doi: 10.1007/s12325-023-02554-6. Epub 2023 Jun 26.

本文引用的文献

J Clin Oncol. 2024 Nov;42(31):3652-3665. doi: 10.1200/JCO.23.02170. Epub 2024 Jun 27.

A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.当前 FDA 批准的抗体药物偶联物综述：具有里程碑意义的临床试验和适应证。

Pharmaceut Med. 2024 Jan;38(1):39-54. doi: 10.1007/s40290-023-00505-8. Epub 2023 Nov 29.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.辅助紫杉醇和曲妥珠单抗用于淋巴结阴性、HER2 阳性乳腺癌：开放标签、单臂、2 期 APT 试验的最终 10 年分析。

Lancet Oncol. 2023 Mar;24(3):273-285. doi: 10.1016/S1470-2045(23)00051-7.

Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT).曲妥珠单抗-恩杂鲁胺或紫杉醇/曲妥珠单抗（ATEMPT）治疗后按年龄分组的治疗中断、患者报告的毒性及生活质量

NPJ Breast Cancer. 2022 Nov 30;8(1):127. doi: 10.1038/s41523-022-00495-x.

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.曲妥珠单抗辅助治疗 HER2 阳性早期乳腺癌的临床研究进展

Breast. 2022 Mar;62 Suppl 1(Suppl 1):S12-S16. doi: 10.1016/j.breast.2022.01.006. Epub 2022 Jan 19.

How we treat patients with metastatic HER2-positive breast cancer.我们如何治疗转移性 HER2 阳性乳腺癌患者。

ESMO Open. 2022 Feb;7(1):100343. doi: 10.1016/j.esmoop.2021.100343. Epub 2022 Jan 4.

Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer.用于预测早期HER2阳性乳腺癌病理反应和生存结果的新型HER2DX检测方法的开发与验证

EBioMedicine. 2022 Jan;75:103801. doi: 10.1016/j.ebiom.2021.103801. Epub 2022 Jan 3.

Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.曲妥珠单抗治疗早期 HER2 阳性乳腺癌：来自 7 项随机试验的 13864 名女性的荟萃分析。

Lancet Oncol. 2021 Aug;22(8):1139-1150. doi: 10.1016/S1470-2045(21)00288-6.

J Clin Oncol. 2021 Jul 20;39(21):2375-2385. doi: 10.1200/JCO.20.03398. Epub 2021 Jun 2.

Randomized Controlled Trial of Trastuzumab With or Without Chemotherapy for HER2-Positive Early Breast Cancer in Older Patients.曲妥珠单抗联合或不联合化疗治疗人表皮生长因子受体 2 阳性老年早期乳腺癌的随机对照试验。

J Clin Oncol. 2020 Nov 10;38(32):3743-3752. doi: 10.1200/JCO.20.00184. Epub 2020 Sep 16.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

T-DM1: a promising adjuvant therapy option for stage I HER2-positive breast cancer-interpreting ATEMPT trial results from a clinical perspective.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

本文引用的文献